A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease

Tanya Simuni*, Kalpana Merchant

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Article number105325
JournalParkinsonism and Related Disorders
Volume108
DOIs
StatePublished - Mar 2023

Funding

Kalpana Merchant, PhD has served as a consultant and/or as a scientific advisory board member for AcureX, Caraway, NRG Therapeutics, Nitrase, Nura Bio, Retromer Therapeutics, Sinopia Biosciences, Vanqua, Vida Ventures and the Michael J. Fox Foundation for Parkinson's Research. She has received research funding from the Michael J. Fox Foundation for Parkinson's Research.

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this